Request for Nominations for Voting Members on a Public Advisory Committee; Technical Electronic Product Radiation Safety Standards Committee, 45249 [2018-19355]

Download as PDF Federal Register / Vol. 83, No. 173 / Thursday, September 6, 2018 / Notices Evaluation, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. G610, Silver Spring, MD 20993–0002, 301–796–6875, email: Patricio.Garcia@fda.hhs.gov. SUPPLEMENTARY INFORMATION: FDA is requesting nominations for voting members on TEPRSSC that include three general public representatives. part 822 have been approved under OMB control number 0910–0449. Dated: August 30, 2018. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2018–19249 Filed 9–5–18; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES I. General Description of the Committee’s Duties Food and Drug Administration [Docket No. FDA–2018–N–3233] Request for Nominations for Voting Members on a Public Advisory Committee; Technical Electronic Product Radiation Safety Standards Committee AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is requesting nominations for members to serve on the Technical Electronic Product Radiation Safety Standards Committee (TEPRSSC) in the Center for Devices and Radiological Health. Nominations will be accepted for current and upcoming vacancies effective with this notice. FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups. DATES: Nominations received on or before November 5, 2018 will be given first consideration for membership on TEPRSSC. Nominations received after November 5, 2018 will be considered for nomination to the committee as later vacancies occur. ADDRESSES: All nominations for membership should be sent electronically by accessing FDA’s Advisory Committee Membership Nomination Portal at https:// www.accessdata.fda.gov/scripts/ FACTRSPortal/FACTRS/index.cfm or by mail to Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103, Silver Spring, MD 20993–0002. Information about becoming a member on an FDA advisory committee can also be obtained by visiting FDA’s website at https:// www.fda.gov/AdvisoryCommittees/ default.htm. FOR FURTHER INFORMATION CONTACT: Patricio G. Garcia, Office of Device daltland on DSKBBV9HB2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 16:56 Sep 05, 2018 Jkt 244001 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees. Dated: August 31, 2018. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2018–19355 Filed 9–5–18; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration The committee provides advice and consultation to the Commissioner of Food and Drugs (Commissioner) on the technical feasibility, reasonableness, and practicability of performance standards for electronic products to control the emission of radiation from such products, and may recommend electronic product radiation safety standards to the Commissioner for consideration. [Docket Nos. FDA–1999–D–0081, FDA– 2008–D–0205, FDA–2018–D–2173, FDA– 2018–D–2236, FDA–2018–D–2238, and FDA– 2018–D–2258] Draft Guidances Relating to the Development of Human Gene Therapy Products; Availability; Extension of Comment Period AGENCY: II. Criteria for Voting Members HHS. The committee consists of a core of 15 voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of science or engineering, applicable to electronic product radiation safety. Members will be invited to serve for overlapping terms of up to 4 years. Terms of more than 2 years are contingent upon the renewal of the committee by appropriate action prior to its expiration. ACTION: III. Nomination Procedures Any interested person may nominate one or more qualified individuals for membership on the committee. Selfnominations are also accepted. Nominations must include a current, complete re´sume´ or curriculum vitae for each nominee, including current business address and/or home address, telephone number, and email address if available, and a signed copy of the Acknowledgement and Consent form available at the FDA Advisory Nomination Portal (see ADDRESSES). Nominations must also specify the advisory committee for which the nominee is recommended. Nominations must also acknowledge that the nominee is aware of the nomination unless self-nominated. FDA will ask potential candidates to provide detailed information concerning such matters related to financial holdings, employment, and research grants and/or contracts to permit evaluation of possible sources of conflicts of interest. This notice is issued under the Federal Advisory Committee Act (5 PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 45249 Food and Drug Administration, Notification; extension of comment period. The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notices of availability for six draft guidance documents relating to the development of human gene therapy products that appeared in the Federal Register of July 12, 2018. The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments and any new information. SUMMARY: FDA is extending the comment period on the six documents that published on July 12, 2018 (see SUPPLEMENTARY INFORMATION). Submit either electronic or written comments by December 10, 2018, to ensure that the Agency considers your comment on these draft guidances before it begins work on the final version of the guidances. DATES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before December 10, 2018. The https://www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of December 10, 2018. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. ADDRESSES: E:\FR\FM\06SEN1.SGM 06SEN1

Agencies

[Federal Register Volume 83, Number 173 (Thursday, September 6, 2018)]
[Notices]
[Page 45249]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-19355]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2018-N-3233]


Request for Nominations for Voting Members on a Public Advisory 
Committee; Technical Electronic Product Radiation Safety Standards 
Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is requesting 
nominations for members to serve on the Technical Electronic Product 
Radiation Safety Standards Committee (TEPRSSC) in the Center for 
Devices and Radiological Health. Nominations will be accepted for 
current and upcoming vacancies effective with this notice.
    FDA seeks to include the views of women and men, members of all 
racial and ethnic groups, and individuals with and without disabilities 
on its advisory committees and, therefore, encourages nominations of 
appropriately qualified candidates from these groups.

DATES: Nominations received on or before November 5, 2018 will be given 
first consideration for membership on TEPRSSC. Nominations received 
after November 5, 2018 will be considered for nomination to the 
committee as later vacancies occur.

ADDRESSES: All nominations for membership should be sent electronically 
by accessing FDA's Advisory Committee Membership Nomination Portal at 
https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm or 
by mail to Advisory Committee Oversight and Management Staff, Food and 
Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103, 
Silver Spring, MD 20993-0002. Information about becoming a member on an 
FDA advisory committee can also be obtained by visiting FDA's website 
at https://www.fda.gov/AdvisoryCommittees/default.htm.

FOR FURTHER INFORMATION CONTACT: Patricio G. Garcia, Office of Device 
Evaluation, Center for Devices and Radiological Health, Food and Drug 
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. G610, Silver 
Spring, MD 20993-0002, 301-796-6875, email: 
[email protected].

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for voting 
members on TEPRSSC that include three general public representatives.

I. General Description of the Committee's Duties

    The committee provides advice and consultation to the Commissioner 
of Food and Drugs (Commissioner) on the technical feasibility, 
reasonableness, and practicability of performance standards for 
electronic products to control the emission of radiation from such 
products, and may recommend electronic product radiation safety 
standards to the Commissioner for consideration.

II. Criteria for Voting Members

    The committee consists of a core of 15 voting members including the 
Chair. Members and the Chair are selected by the Commissioner or 
designee from among authorities knowledgeable in the fields of science 
or engineering, applicable to electronic product radiation safety. 
Members will be invited to serve for overlapping terms of up to 4 
years. Terms of more than 2 years are contingent upon the renewal of 
the committee by appropriate action prior to its expiration.

III. Nomination Procedures

    Any interested person may nominate one or more qualified 
individuals for membership on the committee. Self-nominations are also 
accepted. Nominations must include a current, complete 
r[eacute]sum[eacute] or curriculum vitae for each nominee, including 
current business address and/or home address, telephone number, and 
email address if available, and a signed copy of the Acknowledgement 
and Consent form available at the FDA Advisory Nomination Portal (see 
ADDRESSES). Nominations must also specify the advisory committee for 
which the nominee is recommended. Nominations must also acknowledge 
that the nominee is aware of the nomination unless self-nominated. FDA 
will ask potential candidates to provide detailed information 
concerning such matters related to financial holdings, employment, and 
research grants and/or contracts to permit evaluation of possible 
sources of conflicts of interest.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

    Dated: August 31, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-19355 Filed 9-5-18; 8:45 am]
 BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.